Biocon

Biocon Update: U.S. FDA classifies Johor Bahru facility as VAI

Biocon shares rise 3% as subsidiary secures Japanese PMDA approval for Ustekinumab biosimilar

Biocon Biologics secures PMDA approval for Ustekinumab biosimilar in Japan

Biocon gets VAI status from US FDA for Bengaluru API facility

Biocon shares jump 2% on EU approval for Liraglutide formulation

Biocon and its European partner Zentiva secure EU approval for Liraglutide formulation

Pharma stocks weekly roundup: Biocon leads with 9.08% gain, Torrent Pharma up 4.91%, Lupin dips 1.82%

Biocon shares surge over 3% after Bengaluru facilities get VAI Tag from USFDA

Biocon’s subsidiary refinances USD 1.1 Billion long-term debt through USD bonds and new syndicated facility

Biocon and Tabuk Pharmaceuticals join forces to commercialize GLP-1 products in Middle East markets

LIC increases its stake in Biocon to 5.03%

The Life Insurance Corporation of India (LIC) has announced an increase in its equity shareholding in Biocon Ltd

Biocon shares dip over 2% after US FDA observations

Biocon shares rises after announcing licensing agreement with Handok

Biocon ventures into anti-obesity therapies amid patent expiry wave

Biocon shares surge 2%; check here why